NCT00127881

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Emergent Product Development Seattle LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to treatment with Targretin® and one other standard therapy.

Conditions

• Mycosis Fungoides
• Sezary Syndrome

Interventions

Type	Name	Description
DRUG	HuMax-CD4 (zanolimumab)	Monoclonal Antibody, 12 weekly infusions.

Timeline

• Start date: 2005-07-01
• Primary completion: 2014-02-01
• First posted: 2005-08-09
• Last updated: 2012-07-26

Locations

35 sites across 5 countries: United States, France, Germany, Italy, Spain